EUS

Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test

Retrieved on: 
Lundi, avril 22, 2024
Cancer, Risk, Pancreatic cancer, ELISA, Survival, EUS, Heredity, PDAC, Patient, MRI, Magnetic resonance imaging, CA19-9, Biomarker, Medical imaging

The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.

Key Points: 
  • The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.
  • Importantly, these results confirm the technical advancement of the next-generation test over Immunovia's first-generation test, IMMray PanCan-d.
  • Furthermore, the new test does not provide indeterminate or "borderline" results; all patients are classified as positive or negative for pancreatic cancer.
  • People at risk for pancreatic cancer need a simple, fast, and easy blood test to detect cancer early.

Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test

Retrieved on: 
Lundi, avril 22, 2024
Cancer, Risk, Pancreatic cancer, ELISA, Survival, EUS, Heredity, PDAC, Patient, MRI, Magnetic resonance imaging, CA19-9, Biomarker, Medical imaging

The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.

Key Points: 
  • The Immunovia test was also significantly more accurate than CA19-9, the biomarker commonly used to detect pancreatic cancer.
  • Importantly, these results confirm the technical advancement of the next-generation test over Immunovia's first-generation test, IMMray PanCan-d.
  • Furthermore, the new test does not provide indeterminate or "borderline" results; all patients are classified as positive or negative for pancreatic cancer.
  • People at risk for pancreatic cancer need a simple, fast, and easy blood test to detect cancer early.

Olympus Partners with American Lung Association on Patient Education for Lung Cancer Screening

Retrieved on: 
Mercredi, mars 27, 2024
Diagnosis, Biopsy, Lung cancer, Medicine, Immunotherapy, Disease, Infection, Partnership, Patient, Sore throat, Perforation, Cancer, United, Olympus Corporation, Senior, Lymph, Bleeding, EUS, American Lung Association, Physician, Medical imaging

CENTER VALLEY, Pa., March 27, 2024 /PRNewswire/ -- Olympus Corporation of the Americas, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, is now partnering with the American Lung Association to educate lung cancer patients about the care pathway for diagnosing and staging lung nodules.

Key Points: 
  • The lung nodules educational resources , sponsored by Olympus, help patients understand the diagnosis and staging process for lung nodules and why it is important to their treatment journey.
  • "Olympus is very excited to support this great new educational resource for lung cancer patients through our partnership with the American Lung Association," said Jovan Reyerson, Senior Vice President of Medical and Scientific Affairs at Olympus Corporation of the Americas.
  • Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), a procedure pioneered by Olympus, has helped lay the groundwork for targeted cancer treatment such as immunotherapy.
  • Lung cancer remains the leading cause of cancer death in the United States.² Early detection of lung cancer is key as the 5-year relative survival rate for non-small cell lung cancer is about 65% when caught at a localized stage.

EndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive Officer

Retrieved on: 
Jeudi, février 29, 2024
Medical Devices, Hospitals, Health, Radiology, Health Technology, MD, EVS, Commercial, GI, Organization, EUS, Knowledge, Management

EndoSound™ Inc., a pioneering medical technology company dedicated to advancing patient care, is pleased to announce the appointment of Scott Aldrich Jr as Chief Executive Officer on February 1st, 2024.

Key Points: 
  • EndoSound™ Inc., a pioneering medical technology company dedicated to advancing patient care, is pleased to announce the appointment of Scott Aldrich Jr as Chief Executive Officer on February 1st, 2024.
  • Mr Aldrich is joining EndoSound from MotusGI (Nasdaq: MOTS) where he served as Vice President of Commercial and Strategy.
  • Stephen Steinberg MD will remain on the executive leadership team as Chief Medical Officer.
  • Mr Aldrich brings operational and commercial leadership abilities paired with extensive experience in interventional gastroenterology and medical device imaging.

Canon Medical Systems and Olympus Announce Business Alliance regarding Endoscopic Ultrasound Systems

Retrieved on: 
Lundi, janvier 15, 2024
Oncology, Health, Medical Devices, Technology, Manufacturing, Other Manufacturing, Hardware, Life, Bile, Aplio, Pancreatic cancer, Philosophy, Canon Medical Systems Corporation, Amplitude, Patient, Olympus Corporation, ERCP, MRI, Diagnosis, Attention, Intervention, Gallbladder, Google Images, History, EUS, Jaundice, SMI, Neurosurgery, Endoscopy, Liver, Marketing, Stomach, Duodenum, Pancreas, Physician, Medical imaging

Canon Medical Systems Corporation (Canon Medical) and Olympus Corporation (Olympus), today announced that we have reached an agreement to collaborate on Endoscopic Ultrasound Systems.

Key Points: 
  • Canon Medical Systems Corporation (Canon Medical) and Olympus Corporation (Olympus), today announced that we have reached an agreement to collaborate on Endoscopic Ultrasound Systems.
  • Canon Medical will develop and manufacture diagnostic ultrasound systems used in Endoscopic Ultrasonography1 (EUS), and Olympus will perform the sales and marketing efforts.
  • Canon Medical has a history of more than 100 years in the diagnostic imaging systems business, including X-ray diagnostic systems, CT, MRI, and ultrasound diagnostic systems, and provides products and services to more than 150 countries and regions worldwide.
  • In the field of EUS, diagnostic ultrasound systems are very important, and we are pleased to have a cooperative relationship with Canon Medical, which has advanced ultrasound imaging technology.

EndoSound® Receives 510(k) Clearance for Breakthrough EVS® Innovation, a novel Endoscopic Ultrasound (EUS) technology

Retrieved on: 
Mardi, janvier 2, 2024
Medical Devices, FDA, Health, Health Technology, Clinical Trials, General Health, Liver, Inc., Ecosystem, Gallbladder, ASC, Patient safety, Pancreas, Tissue, Therapy, GI, EVS, Infection, EUS, Patient, Safety, Medical device

The EVS is a novel endoscopic ultrasound (EUS) device that attaches to upper gastrointestinal endoscopes.

Key Points: 
  • The EVS is a novel endoscopic ultrasound (EUS) device that attaches to upper gastrointestinal endoscopes.
  • "We are thrilled to receive 510(k) clearance for our EVS, a testament to the dedication and innovation of the entire EndoSound team.
  • Endoscopic Ultrasound (EUS) is a minimally invasive procedure performed to assess diseases of the GI tract and other nearby organs and tissues.
  • EndoSound is dedicated to expanding access to endoscopic ultrasound technology around the world.

EndoSound and AdaptivEndo Partner to Revolutionize Endoscopy with Groundbreaking Technologies

Retrieved on: 
Jeudi, octobre 12, 2023
General Health, Medical Devices, Health, Clinical Trials, Health Technology, Partnership, Letter, Endoscopy, Infection, Safety, Sterilization, Patient safety, EUS, Patient, Gastroenterology, Medical device

The collaboration between EndoSound and AdaptivEndo recently reached a significant milestone with the successful completion of an in-vivo porcine animal lab.

Key Points: 
  • The collaboration between EndoSound and AdaptivEndo recently reached a significant milestone with the successful completion of an in-vivo porcine animal lab.
  • During this trial, the teams demonstrated their ability to perform EUS with a single-use AdaptivEndo gastroscope and an AdaptivEndo duodenoscope.
  • "The successful in-vivo lab represents a significant leap forward in the field of endoscopy," said Dr. Steve Steinberg, CEO of EndoSound.
  • About AdaptivEndo: AdaptivEndo is a pioneer in single-use endoscopy solutions, offering a range of innovative products designed to improve patient safety and streamline medical procedures.

NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

Retrieved on: 
Jeudi, septembre 28, 2023
PDAC, Pancreatic cancer, AACR, University, Cancer, American Association for Cancer Research, NANO, Monroe Dunaway Anderson, MD Anderson Cancer Center, Radiation, Patient, EUS, Nanobiotix, GTV, IMRT, Neoplasm, NBTXR3, Conference, SD, Safety, Pharmaceutical industry, Euronext, RT

PARIS and CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced new clinical data from a Phase 1 study evaluating radiotherapy-activated NBTXR3 for patients with pancreatic ductal adenocarcinoma (PDAC). The study is being conducted as part of an ongoing collaboration between Nanobiotix and The University of Texas MD Anderson Cancer Center (MD Anderson) and results were presented at the American Association for Cancer Research (AACR) 2023 Special Conference on Pancreatic Cancer.

Key Points: 
  • For the more than 90% of patients with locally advanced disease that is not eligible for surgery (unresectable), there are few treatment options with curative intent.
  • As such, the 5-year overall survival rate for patients with unresectable PDAC remains less than 5%.
  • These patients present an urgent unmet need for new treatment options that provide effective local control with tolerable safety profiles.
  • The Company believes these results support the rationale for further development of NBTXR3 in pancreatic cancer.

Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

Retrieved on: 
Mardi, septembre 26, 2023
Gastrointestinal cancer, MDT, Breakthrough therapy, MBA, GH, Congress, Incidence, Helmy Eltoukhy, Patient, JAMA Network Open, Health, NYSE, Polyp, News, Disease, Oncolytics Biotech, Research, Attention, Biologics license application, MRD, ONC, Pancreatic Cancer Action Network, Data, JD, TSX, FDA, Lancet, GI, Pancreatic cancer, Human, CAD, NSCLC, Biomarker, NRG1, Colorectal cancer, CR, United States Congress, ORR, Clinical trial, FOLFIRINOX, ASCO, American Society of Clinical Oncology, Physician, EUS, Annual general meeting, Poster, Recurrence, Society, FTD, Breast cancer, Pharmaceutical industry, Medical imaging, Meru Networks, Nvidia, Medtronic

VANCOUVER, British Columbia, Sept. 26, 2023 /PRNewswire/ -- USA News Group - The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in April 2023, showing a rising incidence of pancreatic cancer among individuals younger than 55 years. Another study published in JAMA Network Open showed that early-onset cancer in people younger than 50 rose over the last decade, with gastrointestinal cancers seeing the fastest increase. This has led to increased calls from pancreatic cancer organizations such as Pancreatic Cancer Action Network (PanCAN) for more action in the space, including advocating that the US Congress invest more in cancer research funding now. Among the ongoing efforts that are drawing more attention in the pancreatic cancer space have been the developments coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Merus N.V. (NASDAQ: MRUS), Guardant Health, Inc. (NASDAQ: GH), Medtronic plc (NYSE: MDT), and even NVIDIA Corporation (NASDAQ: NVDA).

Key Points: 
  • This has led to increased calls from pancreatic cancer organizations such as Pancreatic Cancer Action Network (PanCAN) for more action in the space, including advocating that the US Congress invest more in cancer research funding now.
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • Pelareorep delivered the company a big win near the end of 2022, when the FDA rewarded it with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • "With a five-year survival rate of 12%, pancreatic cancer patients cannot afford to wait for new treatment options," said Julie Fleshman, JD, MBA, President and CEO of PanCAN.

Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

Retrieved on: 
Mardi, septembre 26, 2023
Gastrointestinal cancer, MDT, Breakthrough therapy, MBA, GH, Congress, Incidence, Helmy Eltoukhy, Patient, JAMA Network Open, Health, NYSE, Polyp, News, Disease, Oncolytics Biotech, Research, Attention, Biologics license application, MRD, ONC, Pancreatic Cancer Action Network, Data, JD, TSX, FDA, Lancet, GI, Pancreatic cancer, Human, CAD, NSCLC, Biomarker, NRG1, Colorectal cancer, CR, United States Congress, ORR, Clinical trial, FOLFIRINOX, ASCO, American Society of Clinical Oncology, Physician, EUS, Annual general meeting, Poster, Recurrence, Society, FTD, Breast cancer, Pharmaceutical industry, Medical imaging, Meru Networks, Nvidia, Medtronic

VANCOUVER, British Columbia, Sept. 26, 2023 /PRNewswire/ -- USA News Group - The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in April 2023, showing a rising incidence of pancreatic cancer among individuals younger than 55 years. Another study published in JAMA Network Open showed that early-onset cancer in people younger than 50 rose over the last decade, with gastrointestinal cancers seeing the fastest increase. This has led to increased calls from pancreatic cancer organizations such as Pancreatic Cancer Action Network (PanCAN) for more action in the space, including advocating that the US Congress invest more in cancer research funding now. Among the ongoing efforts that are drawing more attention in the pancreatic cancer space have been the developments coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Merus N.V. (NASDAQ: MRUS), Guardant Health, Inc. (NASDAQ: GH), Medtronic plc (NYSE: MDT), and even NVIDIA Corporation (NASDAQ: NVDA).

Key Points: 
  • This has led to increased calls from pancreatic cancer organizations such as Pancreatic Cancer Action Network (PanCAN) for more action in the space, including advocating that the US Congress invest more in cancer research funding now.
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • Pelareorep delivered the company a big win near the end of 2022, when the FDA rewarded it with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • "With a five-year survival rate of 12%, pancreatic cancer patients cannot afford to wait for new treatment options," said Julie Fleshman, JD, MBA, President and CEO of PanCAN.